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Dalsan You10, In Gab Jeong10, Jun Hyuk Hong10 & Choung-Soo Kim10
The multi-centre, prospective, observational study was designed to examine the efficacy of continuous 
combined androgen block (CAB) vs. GnRH agonist monotherapy in terms of bone mineral density 
(BMD) change during 12 months post-androgen deprivation therapy (ADT) in Asian prostate cancer 
patients. Multiple regression analysis and estimated the 10-year probability of major fractures among 
the patients with Fracture Risk Assessment Tool were conducted to investigate the underlying factors 
affecting BMD. Paired t-test to evaluate the change of BMD from baseline to 12 month, and two sample 
t-test to examine the difference of BMD changes were used between two groups. BMD significantly 
decreased in both the CAB and GnRH groups, with no group wise differences. The proportion of 
osteopenia or osteoporosis was slightly increased after the 12-month post-ADT. Ten-year probability of 
hip fracture and major osteoporotic fracture was approximately 3% and 5%, respectively. In conclusion, 
a significant decrease of BMD by 12-month ADT was observed without any differences between the 
two groups, whereas ADT-related BMD loss did not induce detrimental effects on bone health in terms 
of increased bone fracture risk. This was the first prospective study on BMD changes as a predictor of 
fracture during ADT in an Asian population.
The worldwide increase in lifespan and improving medical technologies in diagnostic and therapeutic areas such as 
PSA screening facilitate earlier prostate cancer detection resulting in the most rapid increase in cancer among men1. 
Asian countries also showed rapid increase of prostate cancer incidence similar to Western countries, but with 
relatively lower incidence. The annual increase rate of prostate cancer in Korea clearly indicates that prostate can-
cer is the second most rapidly increasing Asian male cancer with an annual increase of 12.3% among all cancers2,3. 
Increasing number of early diagnosed prostate cancer cases have better prognoses, however, a significant portion 
of newly diagnosed patients still have advanced prostate cancer including metastatic disease and androgen depri-
vation therapy (ADT) is a standard treatment for such patients4.
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The ADT comprises two different therapeutic regimens4. One regimen comprises either orchiectomy or 
gonadotropin-releasing hormone (GnRH) agonist that reduces testosterone and oestrogen concentrations; and 
the other of nonsteroidal androgen receptor blocker called bicalutamide that maintains testosterone and oes-
trogen concentrations. The bicalutamide ADT is reportedly less effective than ADT either with orchiectomy or 
GnRH agonist in metastatic diseases. Another combination regimen of strengthening the efficacy was the com-
bined androgen block (CAB) with GnRH agonist plus bicalutamide, which has significant advantages over cas-
tration alone or GnRH agonist monotherapy, such as a higher proportion of patients with complete and partial 
responses, improved control of pain associated with metastatic disease, longer disease-free survival, and longer 
overall survival by an average of 3–6 months, as compared with combined treatment with the anti-androgen 
initiated later4–6.
However, one of the adverse effects of ADT is poor bone health due to significant decreases in bone mineral 
density (BMD) by 1.5–4.0% annually7. Combined with the underlying low BMD presented as osteopenia or 
osteoporosis in mostly old-aged patients with prostate cancer8, ADT-induced bone mineral loss that presents as 
osteopenia or osteoporosis is a major adverse outcome with the increasing risks of serious complications such as 
lumbar and hip fractures9–11. Based on the nationwide analysis of Swedish Prostate Cancer Registry, men on ADT 
represented an additional 30 deaths per 1000 person-years in men who develop hip fractures, as compared with 
an additional 20 deaths per 1000 person-years for hip fractures in the general male population10,11.
Prior experimental work showed that bone turnover markers including urinary N-telopeptide and serum 
osteocalcin are elevated in men receiving GnRH agonist but not in men receiving bicalutamide monotherapy, 
which suggests that bicalutamide monotherapy may maintain BMD and potentially prevent fracture12. However, 
comparative evaluation of BMD loss between treatment groups such as CAB and GnRH agonist monotherapy 
has not been previously conducted. Therefore, the study was aimed to examine the effect of CAB vs. GnRH ago-
nist monotherapy on BMD change and to determine the underlying factors affecting BMD during 12 months 
post-treatment initiation in prostate cancer patients and the 10-year probability of major fractures.
Patients and Methods
Ethical statements. All study protocols were conducted according to the ethical guidelines of the ‘World 
Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects’. 
This study was approved by the ethics committees and the Institutional Review Boards at each hospital (10 
University hospitals in South Korea which were National Cancer Center, Severance Hospital, Konkuk University 
Medical Center, Seoul, Seoul National University Hospital, Seoul St. Mary’s Hospital, Samsung Medical Center, 
Seoul National University Bundang Hospital, Seoul National University Boramae Medical Center, Korea Cancer 
Centre Hospital, and Asan Medical center), that participated in the study, including the Institutional Review 
Board of the Research Institute and Hospital of Asan Medical Center (IRB No. 2010-0210), and all enrolled 
patients provided written informed consent.
Study design. The study was originally designed as a non-inferiority, multi-centre (10 University hospitals in 
metropolitan of Seoul, South Korea which were National Cancer Center, Severance Hospital, Konkuk University 
Medical Center, Seoul, Seoul National University Hospital, Seoul St. Mary’s Hospital, Samsung Medical Center, 
Seoul National University Bundang Hospital, Seoul National University Boramae Medical Center, Korea Cancer 
Centre Hospital, and Asan Medical center), prospective trial on patients who were eligible for study enrolment 
between April 2011 and February 2014. By the statistical calculation performed by medical statistician (SK, PhD), 
416 patients were needed for a one-sided type I error of 2.5% and a power of 90% with − 1.5% of non-inferiority 
margin for change of BMD of L-spine. Assuming a 20% follow-up loss, we needed 500 patients (250 per treatment 
group). However, because of non-intervention and non-randomization nature, the enrolment was imbalanced 
between GnRH group (n = 70) and CAB group (n = 242). Data safety monitoring board (DSMB) reviewed the 
enrolment status and decided to stop the study earlier than planned. Hence, the limited results of this study were 
finally designed as a prospective, non-interventional observation cohort study. The study was also conducted in 
a routine clinical practice without affecting patient treatment. There is no definite standard treatment in terms of 
ADT options including CAB and monotherapy.
Patients’ enrolment criteria. A total of 312 target subjects were pathologically diagnosed prostate cancer 
patients aged ≥ 50, and patients who were scheduled to receive either continuous ADT with CAB (CAB group, 
n = 70) or GnRH agonist monotherapy (GnRH group, N = 242) by each physician’s discretion after considering 
the following criteria: BMD was measured in all patients before ADT initiation. Patients who had a lowered 
T-score ≤ − 3.0 at the time of enrolment and withdrawn their consent were excluded. Patients did not receive 
denosumab or bisphosphonates such as pamidronate or zoledronic acid during ADT. After the 8 subjects with 
exclusion criteria and 51 patients with early drop-out during the study, a final of 253 patients including 196 
patients in the CAB group and 57 patients in the GnRH group completed the study (Table 1).
Bone mineral densitometry. BMD was measured by Dual energy x-ray absorptiometry (DEXA) in 10 
site hospitals. The BMD of L-spine from L1-4 and total, and BMD of femur total and femur neck were measured. 
Using BMD values, T-score and Z-score were calculated by conventional method. The BMD values at baseline 
and at 12M (12th month from treatment initiation) were collected at the study site.
Fracture risk assessment. Estimation of the 10-year probability of major fractures was by the Fracture Risk 
Assessment Tool (FRAX®) with BMD. The factors included age, sex, body mass index, alcohol use, tobacco use, 
glucocorticoid use, rheumatoid arthritis, previous fragility fracture, family history of hip fracture, and secondary 
osteoporosis, and T-score of femur neck BMD.
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Statistical analysis. We evaluated the primary objective as the changes in BMD from baseline to 12-month 
from ADT initiation. The changes from baseline to 12-month were evaluated by paired t-test, and the difference 
between the treatment groups was evaluated by 2 sample t-test. Using the lowest T-score among L-spine total, 
femur total or femur neck at baseline and 12M, BMD status was graded as normal (T-score ≥ − 1.0), osteope-
nia (− 2.5 < T-score < − 1.0), and osteoporosis (T-score ≤ − 2.5)11. In addition, the number and proportion of 
subjects with osteopenia or osteoporosis were analysed with Pearson’s chi-square test. We also evaluated the 
underlying factors affecting BMD changes from baseline to 12M, by multiple regression analysis with treatment 
group, age, weight, and history of smoking and alcohol drinking as independent variables. FRAX® scores of 
baseline, 12M and the change from baseline to 12M by treatment groups were evaluated by paired t-test. The dif-
ference between the treatment groups was evaluated by 2 sample t-test. Additionally, we evaluated the incidence 
of skeletal-related events (SREs) at baseline, 12M and the change from baseline to 12M by treatment group by 
Fisher’s exact test. We adjusted the potential effect of exercise on BMD change by using the International Physical 
Activity Questionnaire (IPAQ).
Parameter CAB group N = 234 GnRH group N = 70 p-value
Age (mean ± SD, Yr) 70.70 ± 7.83 72.24 ± 8.63 0.1593§
 (N,%) 50~59 22 9.40 5 7.14 0.1178‡
60~69 69 29.49 20 28.57
70~79 119 50.85 30 42.86
≥ 80 24 10.26 15 21.43
BMI (mean ± SD, kg/m2) 23.90 ± 2.91 23.77 ± 2.91 0.7507§
Past or present smoking history (N,%) Present smoker 24 10.26 9 12.86 0.2898†
Ex-smoker 88 37.61 32 45.71
Never smoker 122 52.14 29 41.43
Present smoker (N,%) 24 26.69 ± 17.23 9 29.78 ± 14.59 0.6371§
Present non-smoker (N,%) 88 25.32 ± 21.67 32 35.41 ± 29.25 0.0714∫ 
Alcohol consumption (N,%) 128 54.70 44 62.86 0.2271†
Amount of alcohol consumption (N,%) ≥ 2units/day* 52 40.63 10 22.73 0.0329†
< 2units/day* 76 59.38 34 77.27
Fracture history (N,%) 19 8.12 5 7.14 0.7903†
Family history of hip fracture (N,%) 1 0.43 0 0.00 1.0000‡
Concomitant medication (N,%) 96 41.03 38 54.29 0.0499†
Osteoporosis-related concurrent disease (N,%) 3 1.28 1 1.43 1.0000‡
initial PSA (mean ± SD, ng/mL) 213.46 ± 1287.05 30.60 ± 60.15 0.1573∫
Gleason score (mean ± SD) 7.76 ± 1.06 7.77 ± 1.20 0.9671§
Prostate volume (mean ± SD, cc) 52.09 ± 29.16 38.84 ± 16.05 0.0017∫
Clinical stage at diagnosis Tx 3 1.28 0 0.00 0.0616‡
T0 1 0.43 0 0.00
T1 30 12.82 5 7.25
T2 65 27.78 29 42.03
T3 103 44.02 32 46.38
T4 32 13.68 3 4.35
N0 164 70.09 61 88.41 0.0022†
N1 70 29.91 8 11.59
M0 180 76.92 60 86.96 0.0711†
M1 54 23.08 9 13.04
Treatment for prostate cancer Surgery 92 41.63 34 50.75
RRP 46 50.00 25 73.53
LRP 2 2.17 0 0.00
RALP 36 39.13 7 20.59
Other 8 8.70 2 5.88
Radiation 21 9.50 2 2.99
Primary 18 85.71 1 50.00
Palliative 3 14.29 1 50.00
None 116 52.49 32 47.76
Table 1.  Demographic characteristics. §Two sample t-test; ∫ Wilcoxon’s rank sum test; †Pearson’s chi-square 
test; ‡Fisher’s exact test; ♦ Overlapped count; *Alcohol 2 units ≒ beer 1 bottle (500 mL), Korean whisky (Soju) 1/4 
bottle (90 mL), Korean rice wine 1 bottle (500 mL), Wine 2 glasses (200 mL) or Whisky 2 glasses (60 mL)) RRP: 
radical retropubic prostatectomy; LRP: laparoscopic radical prostatectomy; RALP: robotic-assisted laparoscopic 
prostatectomy.
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Results
Baseline characteristics. Among the 253 patients who completed the study, no differences in demographic 
characteristics between treatment CAB (n = 196) and GnRH (n = 57) groups were observed including occurrence 
of osteoporosis-related concurrent disease (p > 0.05, Table 1 and Supplementary Table 1); except for their prostate 
volume (52.09cc in CAB group vs. 38.84cc in GnRH group), clinical N stage (N1, 29.91% vs. 11.59%), mean daily 
alcohol consumption of approximately ≥ 2 units (40.63% vs. 22.73%) and administration of concomitant medica-
tions (41.03% vs. 52.29%) (p < 0.05, Table 1 and Supplementary Tables 1 and 2).
As for the rate of osteoporosis and osteopenia, 39.32% (92/234 subjects) of the CAB group had osteopenia and 
9.40% (22/234 subjects) had osteoporosis at baseline, whereas 41.43% (29/70 subjects) of the GnRH group had 
osteopenia and 8.57% (6/70 subjects) had osteoporosis at baseline.
Changes in BMD. At 12M, the proportion of the subjects with osteopenia or osteoporosis was slightly 
increased, but the difference between the groups was not significant (p = 0.3688; Table 2). As shown in Table 3, 
there were statistically significant mean decrease changes from baseline to 12-month in L-spine total BMD in 
both groups with − 0.04 (SD 0.14) in the CAB group (p < 0.00090) and − 0.05 (SD 0.19) in the GnRH group 
(p < 0.001). The rate of BMD change in L-spine also significantly decreased 2.61% in the CAB group (p < 0.009) 
and 4.37% in the GnRH group (p < 0.0001) with a 95% confidence interval of [− 2.04%, 5.57%]. Non-inferiority 
of the CAB group was undetermined with the lower limit of 95% confident interval of < − 1.5%, however, the 
group wise difference was not statistically significant (p = 0.1518). Furthermore, BMD significantly decreased 
in L1-L4 of both groups, but there were no differences between the 2 groups (p > 0.05; Supplemental Table 3).
The results showed a statistically significant decrease in L-spine total T-score in both groups with 0.34 in the 
CAB group and 0.43 in the GnRH group, respectively (p < 0.0001; Supplemental Table 4). However, the difference 
between the groups was not statistically significant (p = 0.4228).
The changes of each T-score of L1-L4 had the same pattern as total T-score. The L-spine total Z-score 
decreased in both groups with 0.30 in the CAB group (p < 0.0001) and 0.34 in the GnRH group (p = 0.0006), 
without significant differences between treatment groups (p = 0.8123; Supplemental Table 5). Likewise, the BMD 
of total femur and femur neck, T-score and Z-score were significantly decreased from baseline to 12M in both 
groups, with no significant differences between the groups (Supplemental Tables 6, 7 and 8).
Estimated 10-year probability of major fractures. According to FRAX®, the mean 10-year probability 
of major osteoporotic fracture at 12-month was 4.96% and 5.85% in the CAB and GnRH groups, respectively, 
which was not significantly changed from baseline in both groups, with no significant group wise differences 
(p > 0.05, Table 3).
The 10-year probability of hip fracture at 12M was 1.69% and 2.41% in the CAB and GnRH groups, respec-
tively. Significant increase from baseline by 0.20 ± 1.16% (p = 0.0231) was observed in the CAB group, while 
there was no statistically significant change over basal values in the GnRH group, and no differences between 
the groups (p = 0.5531). Two subjects in the GnRH group presented with pathologic fracture and received bone 
surgery with adjuvant radiation therapy at the time of participation. No new SRE occurred in both groups during 
ADT (Supplemental Table 9).
Factors affecting the change in BMD. Factor analysis showed that the treatment group was not a sig-
nificant risk factor for BMD change (p > 0.05, Table 4). For L-spine BMD, there were no factors affecting either 
T-score or Z-score among treatment groups, age, body weight, smoking and alcohol consumption (p > 0.05).
Despite the only significant effect of age on the change in L-spine BMD score (p = 0.0285, Table 4), the clin-
ical effect was insignificant based on the regression estimate. For total femur, similar to L-spine, age was also a 
significant factor affecting the change in BMD (BMD score: p = 0.0445, T-score; p = 0.0372, Z-score: p = 0.0267), 
however, the clinical effect was insignificant (BMD score: e = 0.001, T-score: e = 0.007, Z-score: e = 0.009) 
(Supplemental Table 10). On the other hand, there were no factors affecting the change in BMD (BMD score, 
T-score, Z-score) for femur neck.
Exercise activity. At baseline, 67.52% (158/232 subjects) in the CAB group and 91.43% (64/70 subjects) 
in the GnRH group responded that they performed exercise, which was significantly different (p < 0.0001, 
Supplemental Table 11). At 12-month, 69.35% (138/199 subjects) and 80.70% (46/57 subjects) in the CAB and 
Time Diagnosis
CAB group (N = 234) GnRH group (N = 70)
p-valuen (%) n (%)
Baseline
n 234 70
Normal (T ≥ − 1.0) 120 (51.28) 35 (50.00) 0.9427†
Osteopenia (− 2.5 < T < − 1.0) 92 (39.32) 29 (41.43)
Osteoporosis (T ≤ − 2.5) 22 (9.40) 6 (8.57)
12 month
n 186 55
Normal (T ≥ − 1.0) 81 (43.55) 20 (36.36) 0.3688†
Osteopenia (− 2.5 < T < − 1.0) 81 (43.55) 24 (43.64)
Osteoporosis (T ≤ − 2.5) 24 (12.90) 11 (20.00)
Table 2.  Proportion of osteopenia or osteoporosis. †Pearson’s chi-square test.
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GnRH groups, respectively maintained exercise activity, which was not significantly different (p = 0.0927). In 
order of frequency, exercise of low-intensity was most common, followed by medium- and heavy-intensity.
Discussion
The indications for ADT in prostate cancer treatment have recently extended beyond standard use for palliation 
of metastatic prostate cancer13. Patients with ADT in adjuvant or combined therapy even in earlier stage cancers 
have increased, hence ADT-related side effects including bone health problems such as osteoporosis, lumbar or 
hip fractures by bone mineral loss are also of clinical relevance. This prospective observational study examined 
the effect of CAB vs. GnRH agonist monotherapy on longitudinal BMD change and calculated the 10-year prob-
ability of major fractures to determine the underlying factors affecting the ADT-related, but not tumour-related 
risk factors of BMD change during 12 months post-ADT initiation in prostate cancer patients.
The rapid increase of bone mineral loss and the continuous decrease of BMD within 1 year of ADT initiation 
are well described14. In the literature review of prospective studies, a wide range of BMD changes is influenced in 
patients who received ADT by different types of ADT, period of ADT, and patient ethnicity or presence of bone 
metastasis12–21. In the present study, although the degree of BMD decrease was observed in both, the CAB group 
and GnRH group without any statistical differences between groups (p = 0.8636, Table 2), the total BMD score 
of L-spine showed significantly smaller change in the CAB group, as compared to the GnRH group (p < 0.05, 
Table 2). Many studies on bone mineral loss in patients with prostate cancer have shown that BMD decrease of 
L-spine ranges from 2.40% to 4.80% post-ADT for ≤ 12 months, which was similar to our results of 2.58% in the 
CAB group and 4.37% in the GnRH group14–23.
In spite of the insignificant differences in clinical M stage and significant differences in clinical N stage 
(N1/M1, CAB 29.91%/23.08% vs. GnRH 11.59%13.04%, p = 0.0022/0.0711) between CAB and GnRH groups, 
depending on the presence of bone metastasis, a 6.6% decrease in lumbar spine BMD and a 6.5% decrease in 
femoral neck BMD after 6 months of CAB were observed in patients with bone metastasis14 (Table 1). In patients 
without bone metastases, 2 studies showed that BMD decreases at 12M post-ADT with GnRH agonist were 3.9% 
and 4.8% of total BMD of L-spine, which represents a lower degree of BMD decrease than patients with bone 
metastasis19,22, similar to the degree of BMD decrease in our previous results including cases without bone metas-
tasis8, because the subjects with bone metastasis in our study constituted < 20% of the entire study population.
Ethnic variation including genetic, hormonal or other environmental factors could potentially affect BMD 
change by ADT. African Americans older than 65 years have significantly higher BMD with a similar decline 
in BMD as compared to Caucasians24,25, which may explain the reduced incidence of hip fracture in African 
Americans, as compared to Caucasians25; whereas, another study on Jamaican men showed ADT with lower 
BMD26. Some different cross-sectional Asian studies reported that Short-term ADT of an average 23.5 months 
did not increase the risk of osteoporosis in Japanese prostate cancer patients and ADT was not a significant risk 
factor for decreased BMD27,28. Japanese men exposed to ADT have lower rates of osteoporosis with 2.3% and 8.6% 
in the hormone-naïve and ADT-treated patients, respectively, which was not statistically significant (p = 0.294). 
Variable Time CAB group (N = 234) GnRH group (N = 70)
Difference 95% 
C.I.
Between groups 
p-value¤
Total bone marrow density (BMD) score at L-spine
Changes in total BMD score
n Mean ± SD n Mean ± SD
Baseline 223 1.16 ± 0.25 63 1.15 ± 0.22 0.8636§
12 Month 184 1.13 ± 0.26 55 1.09 ± 0.19
176 − 0.04 ± 0.14 48 − 0.05 ± 0.06 0.01 (− 0.03, 0.06) 0.4887§
Within group 
p-value 0.0009
§§ < 0.0001§§
Rate of BMD change
176 − 2.61 ± 13.11 48 − 4.37 ± 5.04 1.77(− 2.04, 5.57) 0.1518§
Within group 
p− value 0.0090
§§ < 0.0001§§
FRAX® score of major osteoporotic and hip fractures
Major osteoporotic fracture (%)
Baseline 234 5.08 ± 3.14 70 5.35 ± 2.75 0.5194§
12 month 186 4.96 ± 2.84 55 5.85 ± 3.48
change 186 − 0.23 ± 2.79 55 0.20 ± 2.74 0.3189§
Within group 
p-value 0.2635
§§ 0.5973§§
Hip fracture (%)
Baseline 234 1.50 ± 1.54 70 1.87 ± 1.78 0.0943§
12 month 186 1.69 ± 1.76 55 2.41 ± 2.53
change 186 0.20 ± 1.16 55 0.36 ± 1.97 0.5531§
Within group 
p-value 0.0231
§§ 0.1798§§§
Table 3.  Total bone mineral density (BMD) score at L-spine and FRAX® score for major osteoporotic 
and hip fractures. Change = score at 12 month − score at baseline Rate of BMD change = (BMD score at 12 
month − BMD score at baseline)/BMD score at baseline × 100 Difference = CAB group − GnRH group ¤ p-value 
of difference between groups (CAB group − GnRH group): §Two sample t-test §§Paired t-test.
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However, this study showed that the proportion of patients with osteopenia or osteoporosis was insignificantly 
increased slightly at 12M post-ADT initiation between groups (p > 0.05, Table 3) and osteoporosis was 9.4% of 
hormone-naïve Korean prostate cancer patients with an average age of 65.1, which is more common than the 
3.4% of healthy controls in Korea (p = 0.001) and corresponding Japanese prostate cancer patients of an average 
age of 68.18. As shown in literature reviews (Table 5), most prospective ADT studies were composed of patients 
from Western countries using GnRH agonists or orchiectomy, and only a few prospective studies from patients 
with CAB and only a few non-prospective, cross-sectional Asian studies have published their ADT-related results 
of bone mineral loss27–30. This study has clinical relevance because it is the first prospectively designed study of 
longitudinal BMD changes by different types of ADT including CAB and GnRH agonists in Asian patients.
Bicalutamide monotherapy does not facilitate any bone mineral loss, which differs from BMD change due 
to GnRH agonist, orchiectomy or CAB12. There is no prospective study, to the best of our knowledge that com-
pares the rate of bone mineral loss depending on the types of ADT including GnRH agonist, orchiectomy or 
CAB. Instead, one retrospective cohort study including 742 patients presented a higher hazard ratio of frac-
tures in patients treated with CAB than GnRH agonist, but this result may be confounded by pathologic and not 
ADT-related osteoporotic fractures31. A Jamaican cross-sectional study showed GnRH agonist, orchiectomy and 
CAB were a higher risk for osteoporosis than oestrogens or antiandrogen monotherapy. On adjusting for duration 
of therapy, the odd ratio (OR) of CAB was 9.2, as compared to oestrogens as a reference drug (p < 0.003), and 
the 4.5 OR of GnRH agonist (p < 0.04)26. This differed from our finding of no additional risk of CAB, as com-
pared with GnRH agonist monotherapy in terms of bone mineral loss. Although the authors adjusted age and 
duration of ADT treatment, they did not consider various life styles such exercise activity or dietary factors that 
could modify BMD loss due to the limited design of cross-sectional study vs. prospective study. However, in this 
study, we evaluated the characteristics of patient life styles, which further strengthened the study (Tables 1 and 4, 
Supplementary Tables 3 and 12).
Since 2005, large database analyses found an increased risk of developing fracture within 5 years in about 
20% of men starting on ADT32. The prevalence of osteoporosis in men on ADT has substantial variation from 9 
to 53% based on the results of a meta-analysis of 13 reports published from 1999 through 201233. An increased 
proportion of patients with osteopenia or osteoporosis were found at 12M from initiation of ADT, similar to this 
study, which showed slight increase at 12M post-ADT initiation between groups (p > 0.05, Table 2). However, the 
clinical relevance of those changes is necessarily important in terms of fracture risk related with ADT in prostate 
cancer. BMD measurement by DEXA is the standard test for bone health in men on ADT, but there are many con-
cerns of its inaccurate prediction of fracture risk34. The FRAX score in this study developed through risk predic-
tion algorithms that estimate fracture probability using multiple risk factors for fracture, to compensate for this 
limitation of BMD measurement34,35. The National Comprehensive Cancer Center Network and other published 
guidelines recommend screening men receiving ADT according to guidelines from the National Osteoporosis 
Foundation for the general population34. They recommend drug therapy for men with a 10 year probability of hip 
fracture > 3% or a 10 year probability of major osteoporosis-related fracture > 20%, as estimated using FRAX. In 
this study, the 10-year probability of hip fracture at 12M was < 3%, and the 10-year probability of major osteo-
porotic fracture was approximately 5% (Table 3). Accordingly, the BMD loss induced by ADT for 12 months did 
not induce detrimental effects on bone health in terms of increased risk of bone fracture in this study.
Some limitations persist despite the prospective design including multi-centres and its non-interventional 
nature. Firstly, a limited number of patients completed the study and an imbalance in number of subjects per 
group occurred, especially the small number of subjects enrolled in GnRH group. However, the study was basi-
cally designed as a non-interventional and non-randomized study with participants arbitrarily distributed in 
each treatment group. Although the non-inferiority of the CAB group was not determined with statistical signif-
icance through the study, we found a significant decrease in BMD and increased proportion of osteoporosis at 
12M post-ADT. Secondly, we used the FRAX score to estimate the risk of fracture. However, version of Korean 
variable factor Estimate Standard Error p-value
BMD (g/cm2)
Group (1 = CAB group, 0 = GnRH group) 0.019 0.021 0.3699
Age 0.002 0.001 0.0285
Body weight − 0.001 0.001 0.3052
Smoking history (1 = yes, 2 = no) − 0.009 0.021 0.6502
Alcoholic history (1 = yes, 2 = no) − 0.021 0.021 0.3001
Total T-score
Group (1 = CAB group, 0 = GnRH group) 0.118 0.153 0.4432
Age 0.014 0.008 0.0723
Body weight − 0.004 0.007 0.5743
Smoking history (1 = yes, 2 = no) − 0.024 0.152 0.8731
Alcoholic history (1 = yes, 2 = no) − 0.115 0.149 0.4416
Total Z-score
Group (1 = CAB group, 0 = GnRH group) 0.046 0.156 0.7689
Age 0.010 0.008 0.2091
Body weight − 0.007 0.006 0.2669
Smoking history (1 = yes, 2 = no) − 0.007 0.145 0.9617
Alcoholic history (1 = yes, 2 = no) − 0.101 0.144 0.4851
Table 4.  Factors affecting the change in L-spine BMD.
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FRAX® has not been validated yet; hence, a Japanese database was used instead to predict the probability of 
bone fracture score because of the shared similarities of racial and genetic demographics between Koreans and 
Japanese. Thirdly, serum testosterone level was not measurable at the time of ADT start or 12M post-ADT, which 
was important data related to BMD of patients. Lastly, < 20% of subjects with metastasis included could be con-
founding factors for BMD changes by ADT. Fifth, some differences in baseline characteristics such as prostate 
volume, clinical nodal stage, and exercise activity, which are known to be associated with the prevalence of osteo-
porosis, might be underlying confounding factors that were not addressed in this study. However, all information 
obtained from the enrolled patients might predictably indicate that the CAB and GnRH groups would not show 
large baseline differences in parameters related to the prevalence of osteoporosis.
However, this study was clinically meaningful due to its study design as the first prospective study of BMD 
change and the fracture risk during the first 12 months ADT in Asian patients, and as the first detailed infor-
mation about the clinical practice of ADT in Korean Urology, which can potentially be utilized as a reference in 
prostate cancer patients receiving ADT. This study identified that in cases of metastatic disease, Korean urologist’s 
preference for ADT at a university hospital was CAB rather than GnRH agonist monotherapy for improving 
overall survival, as well as palliation4–6. Despite the small proportion of patients with metastatic disease who were 
recruited in this study, many urologists selected CAB rather than GnRH agonist monotherapy for treatment, 
which resulted in failure to recruit sufficient subjects in the GnRH group.
Conclusions
A significant decrease of BMD was observed by 12 months ADT and no difference in BMD loss was found 
between the 2 groups. In particular, there was no clinical significance in terms of increased fracture by 12 months 
ADT. Based on these results, there are no safety concerns of bone-related diseases caused by additional bone loss 
with CAB. In addition, the data collected in this study can potentially be utilized as a reference in patients with 
prostate cancer receiving ADT.
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